Functional loss of p21/Waf-1 in a case of benign canine multicentric melanoma

Veterinary Pathology

Volumn 35, Issue 2, 1998, Pages 94-101

  Ritt, M G ^a   Wojcieszyn, J ^a   Modiano, J F ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Canine; Cyclin dependent kinase inhibitors; Immunoblotting; Immunohistochemistry; Melanoma; Tumor suppressor genes

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CASE REPORT; CELL CULTURE; CHEMISTRY; DOG; DOG DISEASE; FORELIMB; GINGIVA TUMOR; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MICROPHOTOGRAPHY; NOSE TUMOR; PATHOLOGY; PHYSIOLOGY; SKIN TUMOR; TAIL;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOG DISEASES; DOGS; ENZYME INHIBITORS; FORELIMB; GINGIVAL NEOPLASMS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; NOSE NEOPLASMS; ONCOGENE PROTEIN P21(RAS); PHOTOMICROGRAPHY; RETINOBLASTOMA PROTEIN; SKIN NEOPLASMS; TAIL; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032013436     PISSN: 03009858     EISSN: None     Source Type: Journal    
DOI: 10.1177/030098589803500202     Document Type: Article

References (27)

1. Banerjee D, Lenz H-J, Schnieders B, Manno DJ, Ju JF, Spears CP, Hochhauser D, Danenberg K, Danenberg P, Bertino JR: Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Cell Growth Differ 6:1405-1413, 1995
2. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
3. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B: Topological control of p21/waf1/cip1 expression in normal and neoplastic tissues. Cancer Res 55:2910-2919, 1995
4. Goldschmidt MH: Pigmented lesions of the skin. Clin Dermatol 12:507-514, 1994
5. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993
6. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connel-Crowley L, Swindell E, Fox MP, Wei N: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387-400, 1995
7. Hunter T, Pines J: Cyclins and cancer II: cyclin D and cdk inhibitors come of age. Cell 79:573-582, 1994
8. Jacks T, Weinberg RA: Cell-cycle control and its watchman. Nature 381:643-644, 1996
9. Jiang H, Lin J, Su ZZ, Herlyn M, Kerbel RS, Weissman BE, Welch DR, Fisher PB: The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 10:1855-1864, 1995
10. Latchman DS: Transcription-factor mutations and disease. N Engl J Med 334:28-33, 1996
11. Lees E: Cyclin-dependent kinase regulation. Curr Opin Cell Biol 7:773-780, 1995
12. Li Y, Jenkins CW, Nichols MA, Xiong Y: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261-2268, 1994
13. Mittnacht S, Hinds PW, Dowdy SF, Weinberg RA: Modulation of retinoblastoma protein activity during the cell cycle. Cold Spring Harbor Symp Quant Biol 56:197-209, 1991
14. Modiano JF, Domenico J, Szepesi A, Lucas JJ, Gelfand EW: Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells. J Biol Chem 269:32972-32978, 1994
15. Modiano JF, Kolp R, Lamb RJ, Nowell PC: Protein kinase C regulates both production and secretion of interleukin 2. J Biol Chem 266:10552-10561, 1991
16. Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1995
17. Nakanishi M, Adami GR, Robetorye RS, Noda A, Venable SF, Dimitrov D, Pereira-Smith OM, Smith JR: Exit from GO and entry into the cell cycle of cells expressing p21/sdi1 antisense RNA. Proc Natl Acad Sci USA 92: 4352-4356, 1995
18. Ogilvie G, Moore AS: Managing the Veterinary Cancer Patient. Veterinary Learning Systems, Trenton, NJ, 1995
19. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: projections on the hematologic cell lineages. Blood 84: 2391-2411, 1994
20. Ritt MR, Wojcieszyn J, Mayor J, Barton CL, Modiano JF: Expression and subcellular localization of p53 and p21/waf1 in growing versus growth-arrested canine melanoma cells. In: Cellular Immunology and the Immunotherapy of Cancer - III. Keystone Symposia on Molecular and Cellular Biology C2:51, 1997
21. Sherr CJ: G1 phase progression: cycling on cue. Cell 79: 551-555, 1993
22. Waldman T, Kinzler KW, Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55:5187-5190, 1995
23. Waldman T, Lengauer C, Kinzler KW, Vogelstein B: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713-716, 1996
24. Weinberg RA: The cat and mouse games that genes, viruses, and cells play. Cell 88:573-575, 1997
25. Weinberg RA: The molecular basis of oncogenes and tumor suppressor genes. Ann New York Acad Sci 758: 331-338, 1995
26. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81:323-330, 1995
27. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashl R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993